Mass balance and pharmacokinetic characterization of zavegepant in healthy male subjects.
Journal
Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
revised:
29
07
2024
received:
01
04
2024
accepted:
04
08
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
ppublish
Résumé
Zavegepant, a high-affinity, selective, small-molecule calcitonin gene-related peptide receptor antagonist, is approved as a nasal spray for acute treatment of migraine in adults. This phase I, open-label, single-center, single-period, nonrandomized study in six healthy male subjects assessed mass balance recovery after a single 15-min intravenous (IV) infusion dose of carbon-14 ([
Substances chimiques
Calcitonin Gene-Related Peptide Receptor Antagonists
0
Carbon Radioisotopes
0
Azepines
0
Types de publication
Journal Article
Clinical Trial, Phase I
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70015Informations de copyright
© 2024 Pfizer Inc and The Author(s). Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Dodick DW. Migraine. Lancet. 2018;391:1315‐1330.
Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018;58:496‐505.
Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19:17.
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1211‐1259.
Holland PR, Goadsby PJ. Targeted CGRP small molecule antagonists for acute migraine therapy. Neurotherapeutics. 2018;15:304‐312.
Chiang CC, Schwedt TJ. Calcitonin gene‐related peptide (CGRP)‐targeted therapies as preventive and acute treatments for migraine—the monoclonal antibodies and gepants. Prog Brain Res. 2020;255:143‐170.
Ashina M, Terwindt GM, Al‐Karagholi MA, et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet. 2021;39:1496‐1504.
Puledda F, Silva EM, Suwanlaong K, Goadsby PJ. Migraine: from pathophysiology to treatment. J Neurol. 2023;270:3654‐3666.
Goadsby PJ, Holland PR, Martins‐Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97:553‐622.
Charles A, Pozo‐Rosich P. Targeting calcitonin gene‐related peptide: a new era in migraine therapy. Lancet. 2019;394:1765‐1774.
de Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5‐HT beyond the triptans. Pharmacol Ther. 2020;211:107528.
Dhillon S. Zavegepant: first approval. Drugs. 2023;83:825‐831. Erratum in: Drugs. 2023;83:1063.
Scuteri D, Tarsitano A, Tonin P, Bagetta G, Corasaniti MT. Focus on zavegepant: the first intranasal third‐generation gepant. Pain Manag. 2022;12:879‐885.
Zavzpret™ (Zavegepant) Nasal Spray. Prescribing Information. Pfizer Labs. New York, NY. 2023.
Croop R, Madonia J, Stock DA, et al. Zavegepant nasal spray for the acute treatment of migraine: a phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial. Headache. 2022;62:1153‐1163.
Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double‐blind, randomised, placebo‐controlled multicentre trial. Lancet Neurol. 2023;22:209‐217. Erratum in: Lancet Neurol 2023 Jun 29.
Radiological protection in biomedical research. A report of committee 3 adopted by the international commission on radiological protection. Ann ICRP. 1991;22:1‐28, v‐xxiv. Erratum in: Ann ICRP. 1997;27:61.
Coric V, Stock EG, Pultz J, Marcus R, Sheehan DV. Sheehan suicidality tracking scale (Sheehan‐STS): preliminary results from a multicenter clinical trial in generalized anxiety disorder. Psychiatry. 2009;6:26‐31.
Sheehan DV, Giddens JM, Sheehan IS. Status update on the Sheehan‐suicidality tracking scale (S‐STS) 2014. Innov Clin Neurosci. 2014;11:93‐140.
Penner N, Klunk LJ, Prakash C. Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos. 2009;30:185‐203.
Bertz R, Donohue MK, Madonia J, et al. Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of intranasal zavegepant in healthy adults (S31.004). Neurology. 2022;98(18 Supplement):1003.
Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10:1093‐1095.